Latest News - McKesson
Top Corporates Hub
McKesson
RBC Capital Initiates Coverage of McKesson (MCK) with Sector Perform Recommendation
20.08.2026 01:42
How Higher Sales, Lower EPS And New Guidance At McKesson (MCK) Has Changed Its Investment Story
08.08.2026 09:11
On August 5, 2026, McKesson Corporation reported first-quarter fiscal 2027 results showing sales of US$105.38 billion, higher than a year earlier, while net income and earnings per share from continuing operations declined year-on-year. Alongside these results, McKesson completed a large portion of its long-running share repurchase program and raised adjusted earnings guidance, highlighting management’s confidence in specialty and oncology growth, technology and AI investments, and the...
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why
07.08.2026 16:45
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
07.08.2026 13:15
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
McKesson Corp (MCK) (Q1 2027) Earnings Call Highlights: Robust Revenue Growth and Raised ...
06.08.2026 05:14
McKesson Corp (MCK) delivered an 8% revenue increase to $105.4 billion and a 20% adjusted EPS surge, prompting a full-year guidance raise and a 15% dividend boost.
Rising Dividend and Buybacks Might Change The Case For Investing In McKesson (MCK)
25.07.2026 06:10
Earlier this week, McKesson Corporation announced a quarterly dividend of US$0.94 per share, payable on October 1, 2026, to shareholders of record as of the September 1, 2026 ex-dividend and record date. This higher payout highlights how McKesson is combining dividend growth with its existing share repurchase efforts, reinforcing management’s confidence in the company’s earnings power. Against this backdrop of a higher quarterly dividend, we’ll now examine how the announcement interacts with...
Here's Why You Should Add Cencora Stock to Your Portfolio Now
24.07.2026 15:09
COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs
24.07.2026 15:05
RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.
RH Announces the Appointment of Ryan Hassanein as Chief Legal & Compliance Officer
23.07.2026 10:45
CORTE MADERA, Calif., July 23, 2026--RH (NYSE: RH) announced today the appointment of Ryan Hassanein as Chief Legal & Compliance Officer.
Here’s Why McKesson Corporation (MCK) Slid in Q2
16.07.2026 14:36
Janus Henderson Investors, an investment management company, released its second-quarter 2026 investor letter for the “Global Sustainable Equity Fund”. A copy of the letter can be downloaded here. Global equities experienced a robust quarter, with the Fund returning 16.17%, outperforming the Index’s 13.16% gain and the Peer Group’s 12.98% return. An overweight in information technology, particularly AI […]
2 Profitable Stocks Worth Investigating and 1 We Turn Down
15.07.2026 07:26
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
McKesson Releases Fiscal Year 2026 Impact Report
13.07.2026 12:00
IRVING, Texas, July 13, 2026--McKesson published its Fiscal Year 2026 Impact Report, capturing how the company is actively turning purpose into action across healthcare.
Can McKesson (MCK) Stay Cheap After A 338% Five Year Run?
11.07.2026 09:10
McKesson stock has delivered a very large 337.6% total return over the past 5 years, yet the latest valuation checks still suggest the shares lean cheap rather than stretched after that run. Over 5 years, McKesson’s 337.6% return points to a stock that has already rewarded investors heavily, so the key issue is whether today’s price still leaves room for further upside. Expectations around earnings growth supported by capital returns, including buybacks, can support today’s valuation, while...
McKesson (MCK) CEO Sells Shares As Company Names A New Strategy Chief
11.07.2026 02:10
McKesson (NYSE:MCK) disclosed a significant insider sale by its CEO, executed under a pre arranged trading plan. The company also announced the retirement of a key executive and the immediate appointment of a new Chief Strategy Officer. These management moves come alongside an updated company outlook and revised growth targets. McKesson is a major healthcare services and distribution company that connects drug manufacturers, pharmacies, providers, and payers across the supply chain. Insider...
McKesson Stock Is Shrinking, and That's The Point for Owners
09.07.2026 13:24
While the market debates growth, this healthcare giant is steadily retiring its own shares, a strategy that has quietly compounded value for investors.
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
06.07.2026 17:29
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
06.07.2026 16:10
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Defensive Index Additions and TempraMed Deal Change McKesson's (MCK) Risk Perception Narrative
01.07.2026 00:15
In late June 2026, McKesson Corporation was added to several Russell 1000 defensive-style indexes and TempraMed announced an expanded North American distribution partnership with McKesson Medical-Surgical to broaden access to its temperature-controlled medication solutions. These developments highlight McKesson’s role as a key infrastructure provider in healthcare distribution while also reinforcing its positioning in indices focused on defensive characteristics. We’ll now examine how...
McKesson (MCK) Expands TempraMed Partnership Across North America For Full Portfolio Distribution
30.06.2026 14:06
TempraMed Technologies expanded its partnership with McKesson Medical-Surgical, a McKesson (NYSE:MCK) business, to distribute its full portfolio across North America. The agreement focuses on temperature-controlled medication solutions and is intended to strengthen McKesson’s B2B offering to healthcare providers. The expanded distribution supports TempraMed’s move toward a more diversified revenue model while using McKesson’s established medical-surgical network. For investors watching...
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
30.06.2026 07:05
Integration into McKesson's Medical-Surgical Solutions marketplace serving a nationwide customer baseToronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio...